StocksRunner logo
mail
search
 
menu
 
Novo Nordisk A/S Com
$69.64
+0.46%
 
  Create Alerts  
  
  Overview  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
 
 

NVO

 

Novo Nordisk A/S Com

$69.64

 
+$0.32 | +0.46%
 
  Create Alerts  
  
  Overview  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
52W High
$ 143.49
 
 
MKT CAP
$ 239.45B
 
52W Low
$ 57.00
 
 
VOL
$ 8.96M
 
P/E Ratio
18.9
 
 
AVG VOL
$ 8.78M
 
RSI
46.76
 
 
TREND
Sideways
 
 
 

Chart

 
 

$68.17   (+2.16%)

$65.09   (+6.99%)

$89.55   (-22.23%)

$131.54   (-47.06%)

 
 
1year
6month
3month
1month
 
NVO Latest Analysis +
 
 
 
StocksRunner

Explore our NVO Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored NVO Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our NVO Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Plans & Pricing

Contact Us

Terms of use

Privacy Policy

 
 
StocksRunner
 
 
StocksRunner Overview
 
StocksRunner Trending
 
StocksRunner Screener
 
StocksRunner Insights
 
StocksRunner Top Rated
 
StocksRunner Momentum
 
StocksRunner Earnings
mail
 
 

NVO

 

Novo Nordisk A/S Com

 
 

Current Price

 

$69.64

 
+$0.32 | +0.46%
 
NVO Rating Score

Buy

 
52W High
$ 143.49
 
 
MKT CAP
$ 239.45B
 
52W Low
$ 57.00
 
 
VOL
$ 8.96M
 
P/E Ratio
18.9
 
 
AVG VOL
$ 8.78M
 
RSI
46.76
 
 
TREND
Sideways
 
 
 
  Create Alerts  
  
  Overview  
  
  Insights  
  
   Risks   
  
  Rating  
  
  Chart  
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
 
 
 
 
 
 

NVO Stock Rating

 
lock  Login to view Novo Nordisk A/S Com (NVO) recommendation from the last 90 days from financial news and social media.
 

Chart

 
 

$68.17   (+2.16%)

$65.09   (+6.99%)

$89.55   (-22.23%)

$131.54   (-47.06%)

 
 
1year
6month
3month
1month
 
 
 
 
 

NVO Latest Analysis

 
 
 

Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval. ) on Tuesday announced that it has submitted an application to the European Medicines Agency (EMA) for approval of a new higher Wegovy (subcutaneous semaglutide 7.2 mg).The submission is based on clinical data from the STEP UP and STEP UP T2D trials investigating the efficacy and safety of semaglutide 7.2 mg in adults with obesity in STEP UP and adults with obesity and type 2 diabetes in STEP UP T2D.In

 

Today

$69.64 | +0.46%
 
Activity

Why Novo Nordisk (NVO) is a Top Value Stock for the Long-Term. Whether youre a value growth or momentum investor finding strong stocks becomes easier with the Zacks Style Scores a top feature of the Zacks Premium research service.

 

Mon Jul 7, 2025

$69.27 | +0.14%
 
Potential

Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits. ) is currently experiencing a decline in its stock price trading lower on Monday. The company’.s stock has plummeted approximately 18% over the past month reflecting recent challenges.A significant development contributing to this decline occurred in June 2025 when ) ended its collaboration with Hims &. Hers. Consequently Hims &. Hers will no longer have direct access to Wegovy Novo Nordisk’.s popular GLP-1 weig

 

Mon Jul 7, 2025

$69.27 | +0.14%
 
Activity
Potential

Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report. ) executives allegedly ignored internal warnings that the company was unprepared to launch its .As rival ) Zepbound gains momentum the Danish pharmaceutical giant is grappling with the fallout of those early decisions.Wegovy approved in the United States in mid-2021 marked a major advancement in obesity treatment and helped Novo generate $46 billion in net profit since then.Also Read: But the company has struggled to k

 

Tue Jul 1, 2025

$69.84 | +1.16%
 
Activity
Activity

Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever.

 

Tue Jul 1, 2025

$69.84 | +1.16%
 
Earnings

Novo Nordisk continues efforts to support patient access to authentic FDA approved Wegovy® and prioritize patient safety. Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy Ro and LifeMD collaborations continue based on their commitment to providing safe and effective medical treatment for patients living...

 

Thu Jun 26, 2025

$67.70 | +0.49%
 
Activity

Why Hims & Hers Stock Is Crashing and Is It a Buying Opportunity?. Novo Nordisk (NYSE: NVO) severed its partnership with Hims &. Hers (NYSE: HIMS) arguing that the company breached the agreement between the two.

 

Thu Jun 26, 2025

$67.70 | +0.49%
 
Activity
Momentum

After Its Biggest Drop Ever...Is HIMS A Buy?. HIMS just suffered the biggest single-day drop in its trading history a

Hims &. Hers Health(NYSE:) After $NVO Novo Nordisk abruptly terminated their partnership citing deceptive marketing Hims &. Hers fired back with confidence saying they'.llIn interviews and public posts Dudum called the termination misleading and pulled back the curtain onThey were pushing us to a degree that was uncomfortable. They'.ve be

 

Wed Jun 25, 2025

$67.35 | -4.78%
 
Activity
Activity

Novo Nordisk stock falls after Spain probes obesity awareness campaign.

 

Wed Jun 25, 2025

$67.35 | -4.78%
 
Momentum

Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?. NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy hitting patient access and market share plans.

 

Tue Jun 24, 2025

$70.73 | +1.45%
 
Activity

 
 
 
 
 
StocksRunner

Discover NVO Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of NVO. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our NVO Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

NVO Stock trends

NVO Stock performance

NVO Stock analysis

NVO investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo
 

UnAlert NVO Runner Alarm

Real-time signals powered by data
×

Price-Based

Triggers when the stock breaks through a known resistance level
 
Triggers when the stock drops below a key support level
 
Notifies if the stock moves up/down by a set percentage (e.g. ±5%)
 
Alerts when the stock hits a new high or low
 
Signals proximity to long-term highs or lows (e.g. within 5%)
 

Technical Indicator (Pro Plan)

Volume spikes 2x–3x above average. Indicates strong buying/selling pressure
 
Tracks large intraday swings, signaling potential opportunities or risk
 
Signals potential trend reversals or continuations
 
Long-term bullish/bearish trend signals from MA crossovers
 
RSI above 70 or below 30 to identify possible reversals
 
Signals momentum shifts
 

Fundamental (Master Plan)

Upcoming or just-released earnings reports
 
Alerts after results compared to expectations
 
Changes in rating or target price
 
New or changed dividends
 
Large trades by company insiders
 
M&A, lawsuits, product launches, etc
 
High volume/open interest in call/put contracts
 
Surge in mentions or sentiment shifts
 

 
 
Post ×
 
0/666
joker
 
 
 
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Credibility Score

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing NVO

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

 
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Credibility Score

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing NVO

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.